Research graph
References from Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
10.1056/nejmoa1006448 · 2010 · External reference
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
10.1016/j.cell.2007.11.025 · 2007 · External reference
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
10.1200/jco.2009.22.6993 · 2009 · External reference
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
10.1038/nature05945 · 2007 · External reference
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
10.1016/s1470-2045(15)00488-x · 2016 · External reference
Ceritinib in ALK-rearranged non-small-cell lung cancer
10.1056/nejmoa1311107 · 2014 · External reference
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
10.1056/nejmoa1214886 · 2013 · External reference
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond
2014 · External reference
Alectinib:. a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically acquired resistance
10.1016/j.apsb.2014.12.007 · 2015 · External reference
FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer
10.1158/1078-0432.ccr-14-3157 · 2015 · External reference
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
10.1016/s1470-2045(15)00614-2 · 2016 · External reference
Final overall survival and other efficacy and safety results from ASCEND-3: Phase II study of ceritinib in ALKi-naive patients with ALK-rearranged NSCLC
10.1016/j.jtho.2019.11.006 · 2020 · External reference
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
10.1016/s0140-6736(17)30123-x · 2017 · External reference
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial
10.1158/1078-0432.690.11.2 · 2005 · External reference
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
10.1200/jco.2007.15.0375 · 2008 · External reference
A confidence interval for the median survival time
10.2307/2530286 · 1982 · External reference
Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: the role of systemic progression control
10.1111/1759-7714.13221 · 2019 · External reference
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
10.1016/s2213-2600(19)30053-0 · 2019 · External reference
Alectinib (ALC) vs crizotinib (CRZ) in treatment-naive ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study
10.1093/annonc/mdx729.009 · 2017 · External reference
Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer
10.1016/j.jtho.2018.06.012 · 2018 · External reference
Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer
10.4143/crt.2017.280 · 2018 · External reference
ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC)
10.1016/j.jtho.2017.07.005 · 2017 · External reference
Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-positive NSCLC: primary efficacy results from the ASCEND-8 study
10.1016/j.jtho.2019.03.002 · 2019 · External reference
ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: a clinical perspective
2019 · External reference
Cost effectiveness of ceritinib and alectinib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
10.1007/s40261-019-00880-8 · 2020 · External reference
